Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

495

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Masitinib (6.0)
DRUG: Riluzole
DRUG: Placebo
DRUG: Masitinib (4.5)

Sponsor

AB Science